Any negotiation for new industry agreements in Australia will be set against the backdrop of a highly complex global environment, including US demands for higher prices. For many Australian-based affiliates, the threshold question might focus on whether their global organisations will even allow them to support any negotiation not premised on higher prices. …
The next negotiation was always going to be complicated, the new reality will make it more so
August 25, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
The PBS stands alone as the only major health and disability program going backwards
October 13, 2026 - - Latest News -
GBMA's Nikki Lorenz returns from global generics talks with WHO and WTO
October 13, 2026 - - Latest News -
Australian children with cancer are missing out on trials adults can access
October 13, 2026 - - Latest News